Last reviewed · How we verify
NCT04475211: LICORNE
LILLE COVID RESEARCH NETWORK (Covid-19)
trial in Sars-CoV2 in 757 participants. Completed in 15 June 2022.
15 June 2022
Quick facts
| Lead sponsor | University Hospital, Lille |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 757 |
| Start date | 10 August 2020 |
| Primary completion | 15 June 2022 |
| Estimated completion | 15 June 2022 |
| Sites | 1 location across France |
Conditions studied
- Sars-CoV2 — all drugs for Sars-CoV2 →
Sponsor
University Hospital, Lille
Who can join
18 and older, any sex, with Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Lille University Hospital developped a research objective common to all the services which took care of patients, "suspected patient", "possible case", "probable case" or "confirmed case" infected with SARS-CoV-2 by constituting a prospective and a retrospective observational cohort which allowed pooling and sharing the resources and data collected. In the next two years the prospective cohort will allow to continue inclusions in a standardized way mainly for the constitution of a negative control group (excluded cases), to collect biological samples which had not been collected in the retrospective cohort so that the pathophysiology of the COVID-19 will be better apprehended as for example the inflammatory response to the viral infection. Finally in case of a second epidemic wave in the Hauts De France, it seems essential to have a defined research protocol which had already received all the necessary authorizations to guarantee cutting-edge (or quality ) research in a center like the Lille University Hospital.The aim objective of this study is to identify predictive factors of mortality to day 28 infection to SARS-CoV-2 for patients under medical care for the COVID-19 in the Lille University Hospital thanks to the constitution of an epidemiological, clinical, biological, immunological, genetic, microbiological, anatomopathologic, radiological, therapeutic database and so record the results of functional exploration exams.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential.
Hussain I, Cher GLY, Abid MA, Abid MB. · · 2021 · cited 53× · PMID 34721437 · DOI 10.3389/fimmu.2021.765965
Verify or expand the search:
- PubMed search for NCT04475211
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sars-CoV2
Currently open trials in the same condition.
- NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
- NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
- NCT04363853 — Tocilizumab Treatment in Patients With COVID-19 · Phase 2 · active not recruiting
- NCT04424992 — The Natural History of Hospitalized COVID-19 Patients · recruiting
Other University Hospital, Lille trials
Trials by the same sponsor.
- NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
- NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
- NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
- NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
- NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04475211 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04475211.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing